• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

AstraZeneca

1,510.50 SEK+2.48 %4/8 17:29
Less than 1K followers

AZN

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+2.48 %
-18.92 %
-12.86 %
-10.54 %
-11.33 %
+5.89 %
+1.65 %
+52.19 %
+8,165.16 %

AstraZeneca is a global pharmaceutical company focused on the research, development and marketing of prescription medicines, primarily for the treatment of diseases in the therapeutic areas of respiratory, cardiovascular/metabolic and cancer. In addition to its core business, the company also has a focus on the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in all global regions and is headquartered in Cambridge, UK.

Read more
Market cap
2.34T SEK
Turnover
2.39B SEK
Revenue
540.24B
EBIT %
23.4 %
P/E
24.88
Dividend yield-%
1.95 %
Revenue and EBIT-%
EPS and dividend
Financial calendar
6/8
2026

Half year dividend

30/10
2026

Interim report Q3'26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release2026-07-31 08:35

AstraZeneca: Datroway[ ]approved in the EU as only TROP2-directed medicine with overall survival benefit for the 1st-line treatment of patients with metastatic TNBC who are not candidates for immunotherapy

AstraZeneca
Press release2026-07-27 08:10

AstraZeneca: Update on Phase III trial of Ultomiris in adults and adolescents with thrombotic microangiopathy after haematopoietic stem cell transplant

AstraZeneca
Press release2026-07-27 08:06

AstraZeneca: Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers

AstraZeneca

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release2026-07-27 08:00

Resultat för AstraZeneca: Första halvåret samt andra kvartalet 2026

AstraZeneca
Regulatory press release2026-07-27 08:00

AstraZeneca: Half-year Financial Report

AstraZeneca
Press release2026-07-24 13:09

AstraZeneca: Enhertu plus pertuzumab recommended for approval in the EU by CHMP as 1st-line treatment for patients with HER2-positive metastatic breast cancer

AstraZeneca
Press release2026-07-24 12:45

AstraZeneca: Trixeo recommended for approval in the EU by CHMP for the maintenance treatment of asthma

AstraZeneca
Press release2026-07-23 08:06

AstraZeneca: Etcamah (camizestrant) in combination with a CDK4/6 inhibitor approved in the EU for 1st-line advanced ER-positive breast cancer

AstraZeneca
Press release2026-07-14 08:09

AstraZeneca enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical

AstraZeneca
Press release2026-07-09 08:07

AstraZeneca: Update on CARDIO-TTRansform Phase III trial for Wainua (eplontersen) in adults with transthyretin-mediated amyloid cardiomyopathy

AstraZeneca
Press release2026-06-29 08:49

Efzimfotase alfa showed bone health improvements in treatment-naïve paediatric patients with hypophosphatasia: median difference of 1.67 vs placebo in RGI-C Score at week 25 in MULBERRY Phase 3 trial

AstraZeneca
Press release2026-06-29 08:38

AstraZeneca: Enhertu approved in the EU as first tumour agnostic HER2-directed therapy and antibody drug conjugate for patients with previously treated HER2-positive metastatic solid tumours

AstraZeneca
Press release2026-06-26 13:15

AstraZeneca: Datroway[ ]recommended for approval in the EU by CHMP as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy

AstraZeneca
Press release2026-06-15 08:12

AstraZeneca: Ultomiris granted Priority Review in the US as treatment for adults with immunoglobulin A nephropathy

AstraZeneca
Press release2026-06-15 08:07

AstraZeneca: Truqap combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer

AstraZeneca
Press release2026-06-08 22:21

Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme and unlocks next chapter in AstraZeneca's cardiometabolic and kidney portfolio

AstraZeneca
Press release2026-06-06 10:35

AstraZeneca: Ultomiris demonstrated 43.4% reduction in proteinuria vs placebo in adults with immunoglobulin A nephropathy at 34 weeks in I CAN Phase III trial

AstraZeneca
Press release2026-06-02 14:06

AstraZeneca: Camizestrant combination delayed time to first progression by 55% and to second progression by 37% in patients with advanced HR-positive breast cancer with an emergent ESR1 mutation in SERENA-6 trial

AstraZeneca
Press release2026-06-01 14:11

AstraZeneca: Imfinzi plus Imjudo combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolisation-eligible unresectable liver cancer in EMERALD-3 Phase III trial

AstraZeneca
Press release2026-05-29 14:08

AstraZeneca: CARES Phase III clinical programme did not meet primary endpoint in overall AL amyloidosis population, however, demonstrated anselamimab as potential first anti-fibril therapy in kappa AL amyloidosis

AstraZeneca